Finn
MRNA Biotechnology · Biotech · Vaccines · mRNA platform · Thesis updated November 8, 2026

Moderna cuts costs and preps cancer data while COVID fades

01 Running thesis

A platform under pressure

Moderna is trying to turn its COVID windfall into a lasting biotech business. The bull case relies on the mRNA platform producing new products. The company now has five approved vaccines, and Q3 2026 offered a positive signal as management raised full-year revenue growth guidance to a range of 15 to 25 percent. The company also lowered its 2026 cash cost guidance to $3.8 billion.

The newest commercial win is mFLUSIVA, a seasonal flu vaccine approved in the U.S. and Canada. If it gains use alongside mCOMBRIAX in upcoming respiratory seasons, Moderna can prove that its platform sells more than stand-alone COVID shots. A major boost to the bull case came from a Phase 3 melanoma trial, which showed a 42 percent reduction in the risk of recurrence or death.

The bear case is still hard to ignore. Q2 2026 product sales were extremely weak at $94 million, and the RSV vaccine added only $3 million. Meanwhile, the norovirus vaccine halted enrollment for an additional cohort, introducing delays and competitive questions.

The next year is mostly about proof. Investors will watch for a melanoma therapy submission targeted for late 2026, data from a propionic acidemia trial, and regulatory feedback on U.S. filing strategies for the flu and COVID combo vaccine.

Nov 2026▲Q3 2026 results strengthened the bull case with positive Phase 3 melanoma data, a fifth product approval in mFLUSIVA, and raised revenue guidance.
Jul 2026→Moderna lowered its 2026 cash cost estimate to $4 billion. A unanimous FDA committee backing for the flu vaccine was offset by a Phase 3 delay in the norovirus program.
May 2026▲Q1 2026 confirmed the transition story. Revenue rose to $389 million, management repeated guidance for up to 10% revenue growth in 2026, and mCOMBRIAX became Moderna's fourth approved product.
May 2026→The same filing showed the cost of the transition. Moderna reported a $1.3 billion net loss, including the $950 million Arbutus and Genevant settlement payable in Q3 2026.
Feb 2026▼The 2025 10-K showed revenue falling to $1.9 billion from $3.2 billion and a full-year net loss of $2.8 billion. RSV sales were only $8 million, which kept commercial execution risk high.
Nov 2025▼The Phase 3 congenital CMV vaccine trial failed its main goal, and Moderna discontinued that program. This raised the risk around non-respiratory pipeline success.
Aug 2025→mNEXSPIKE was approved, and mRESVIA received an expanded label, but Q2 revenue fell to $114 million. The BARDA pandemic flu contract termination added funding pressure.
May 2025→Cost cuts and the lifted norovirus clinical hold helped the bull case. Very weak RSV sales and lower product revenue kept the bear case alive.
02 Business model

Selling shots while funding science

Moderna makes money by selling vaccines based on messenger RNA, or mRNA. mRNA is a set of instructions that tells cells to make a target protein, so the immune system can learn what to fight.

Today the business is still mostly a respiratory vaccine company. Its approved products are Spikevax for COVID, mNEXSPIKE as a next-generation COVID shot, mRESVIA for RSV, mCOMBRIAX for flu plus COVID, and mFLUSIVA for seasonal influenza.

The model works only if new products can replace shrinking COVID demand. That is why cost control matters. Management recently lowered 2026 cash cost guidance to approximately $3.8 billion, reflecting operational improvements in research and manufacturing. A recent $2.6 billion net convertible debt raise further protects the balance sheet.

Moderna is also using partners where it makes sense. Its Recordati deal for mRNA-3927, a propionic acidemia therapy, lets Moderna lead clinical development while Recordati would help with global commercialization if approved.

03 Product portfolio

Five products, many bets

Cash cow

Spikevax

Spikevax is Moderna's original COVID-19 vaccine. Sales have moved from a pandemic surge to a smaller seasonal market.

Steady

mNEXSPIKE

mNEXSPIKE is the next-generation COVID vaccine launched in Q3 2025. Moderna says it became its leading U.S. retail channel product in 2025.

Option

mRESVIA

mRESVIA is the RSV vaccine. It is approved for adults 60 and older, but early commercial sales have been minimal.

Growth engine

mCOMBRIAX

mCOMBRIAX combines flu and COVID protection in one shot. It is approved in Europe and Canada.

Growth engine

mFLUSIVA

mFLUSIVA is a seasonal influenza vaccine. It received approval in the U.S. and Canada, becoming the fifth commercial product.

Option

mRNA-4157 (Intismeran)

mRNA-4157 is an individualized cancer therapy partnered with Merck. Phase 3 melanoma data showed a significant reduction in recurrence or death.

Option

mRNA-3927 rare disease therapy

mRNA-3927 targets propionic acidemia, a rare disease. Its registrational study has reached target enrollment, with data expected in late 2026.

04 Business segments

Still a COVID-heavy mix

COVID vaccines97%declining
RSV vaccine3%declining

Moderna reports as one operating segment. The product-sales mix shown here is from Q2 2026 net product sales of $94 million, made up of $91 million from COVID vaccines and $3 million from mRESVIA.

05 Risk factors

What could break the story

New vaccines do not sell

High impact · High odds

The biggest risk is commercial. mRESVIA entered an RSV market already served by two larger competitors, and early sales were weak. mCOMBRIAX and mFLUSIVA may face the same problem if doctors and pharmacies stick with older alternatives.

We watchTrack mRESVIA, mCOMBRIAX, and mFLUSIVA product sales during each respiratory season.

Losses drain the cash runway

High impact · Medium odds

Moderna is cutting costs, but the company is still losing a lot of money. The company recently raised convertible debt to bolster cash. If revenue growth stalls, cost cuts may not be enough to reach profitability.

We watchWatch quarterly net loss, adjusted cash costs, and cash balances.

The pipeline misses again

High impact · Medium odds

The norovirus vaccine recently halted enrollment for an additional cohort, mirroring an earlier failure in the CMV vaccine trial. The remaining late-stage bets now carry more weight. A miss in melanoma or rare disease would hurt the bull case.

We watchWatch late 2026 regulatory submissions for mRNA-4157 and data readouts for mRNA-3927.

Pricing rules cut vaccine revenue

Medium impact · Medium odds

Moderna warned that U.S. drug pricing reforms could hurt revenue. These models can tie U.S. prices to lower prices in other countries. That matters because the U.S. is often a key profit pool for vaccines and biotech drugs.

We watchWatch U.S. drug pricing proposals that include vaccine products or international price links.
06 Quick answers

In one breath

What does Moderna actually sell now?

Moderna sells COVID vaccines, an RSV vaccine, a seasonal flu vaccine, and a flu plus COVID combo vaccine. COVID vaccines still make up nearly all product sales based on recent quarters.

Why is Moderna still losing money?

COVID demand is much lower than during the pandemic, while Moderna still spends heavily on research, trials, and new launches. The company is actively cutting cash costs to manage these losses.

What is Moderna's biggest upcoming catalyst?

The clearest near-term catalyst is a planned late 2026 regulatory submission for Intismeran, an individualized cancer therapy for melanoma. Investors will also watch late-stage clinical data in rare diseases.

Is Moderna only a COVID company?

No, but it still depends heavily on COVID vaccine sales today. The investment case is about whether flu, combo vaccines, cancer therapy, and rare disease programs can create a new revenue base.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Moderna Q3 2026 earnings call transcript
  2. Moderna Q2 2026 Form 10-Q
  3. Moderna 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Moderna, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today